Toxoplasmosis – A Global Threat. Correlation of Latent Toxoplasmosis with Specific Disease Burden in a Set of 88 Countries

Jaroslav Flegr1,*, Joseph Prandota2, Michaela Sovickova1, Zafar H. Israili3

1 Department of Biology, Faculty of Science, Charles University in Prague, Prague, Czech Republic, 2 Department of Social Pediatrics, Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland, 3 Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, United States of America

Abstract

Background: Toxoplasmosis is becoming a global health hazard as it infects 30–50% of the world human population. Clinically, the life-long presence of the parasite in tissues of a majority of infected individuals is usually considered asymptomatic. However, a number of studies show that this ‘asymptomatic infection’ may also lead to development of other human pathologies.

Aims of the Study: The purpose of the study was to collect available geopiodemiological data on seroprevalence of toxoplasmosis and search for its relationship with mortality and disability rates in different countries.

Methods and Findings: Prevalence data published between 1995–2008 for women in child-bearing age were collected for 88 countries (29 European). The association between prevalence of toxoplasmosis and specific disease burden estimated with age-standardized Disabled Adjusted Life Year (DALY) or with mortality, was calculated using General Linear Method with Gross Domestic Product per capita (GDP), geolatitude and humidity as covariates, and also using nonparametric partial Kendall correlation test with GDP as a covariate. The prevalence of toxoplasmosis correlated with specific disease burden in particular countries explaining 23% of variability in disease burden in Europe. The analyses revealed that for example, DALY of 23 of 128 analyzed diseases and disease categories on the WHO list showed correlations (18 positive, 5 negative) with prevalence of toxoplasmosis and another 12 diseases showed positive trends (p<0.1). For several obtained significant correlations between the seroprevalence of toxoplasmosis and specific diseases/clinical entities, possible pathophysiological, biochemical and molecular explanations are presented.

Conclusions: The seroprevalence of toxoplasmosis correlated with various disease burden. Statistical associations does not necessarily mean causality. The precautionary principle suggests however that possible role of toxoplasmosis as a triggering factor responsible for development of several clinical entities deserves much more attention and financial support both in everyday medical practice and future clinical research.

Introduction

Toxoplasmosis, a disease caused by the obligate apicomplexan intracellular protozoan Toxoplasma gondii, is one of the world’s most common parasites infecting most genera of warm-blooded animals (more than 30 species of birds and 300 species of mammals). It is the most prevalent infection in humans (estimated to be 30–50% of the world population), more than latent tuberculosis which infects about one-third of the human population (WHO, www.who.int/entity/tb/publications/2009/tbfactsheet_2009update_one_page.pdf, accessed July 2013). The definitive hosts are representatives of the felid (cat) family. Nicolle and Manceaux (1908) first observed the parasites in the blood and tissues of a North African rodent, Ctenodactylus gondii, and named it Toxoplasma (arclike form) gondii (after the rodent host) [1]. There are three infective stages of T. gondii: a) a rapidly dividing invasive tachyzoite; b) a slowly dividing bradyzoite in tissue cysts, which can persist inside human cells for protracted periods; and c) an environmental stage, the sporozoite, protected inside an oocyst. The oocysts, remarkably stable environmentally, are transmitted to other hosts through inadvertent ingestion.

Seroprevalence of toxoplasmosis

Seroprevalence is a measure of the accumulated exposure during a person’s lifetime in a particular social setting. Most of the more than one third of the world’s human population who are infected with T. gondii remain asymptomatic because the immune system usually keeps the parasite from causing illness. Chronic, usually lifelong, infection with Toxoplasma that is not accompanied with overt clinical symptoms of toxoplasmosis disease is termed latent toxoplasmosis while chronic infection associated with...
continuous or recurrent clinical symptoms is termed chronic toxoplasmosis (this form of disease is relatively rare in Europe and Northern America). Worldwide seroprevalence of the parasite measured by specific anti-Toxoplasma IgG antibodies varies between 1% and 100% depending on the environmental and socioeconomic conditions, including eating habits and health-related practices [2–5], general level of hygiene, host susceptibility, geographical location (geolatitude) and humidity of the soil. The incidence of infection is higher in warmer and humider climates and increases with age [5]. The lowest seroprevalence (~1%) was found in some countries in the Far East and the highest (>90%) in some parts of European and South American countries. In the United States, the Centers for Disease Control and Prevention (CDC) reported an overall seroprevalence of 11% [National Health and Nutritional Examination Survey between 1999 and 2004]; another survey reported a higher number (22.5%) [6]. Nevertheless, toxoplasmosis is one of the leading causes of death attributed to foodborne illness [7]. In European countries, the prevalence ranges between 10% to 60%, and in some regions as high as 90% [8]. In one study, 84% of pregnant women had serum antibodies against the parasite [3]. Data from 38 countries are presented in Table 1; most of the published data on seroprevalence are in women of childbearing age and/or those who are pregnant.

In the majority of the human populations, the parasite seroprevalence increases with age, and may vary by gender [6,94]. Latitudinal variability in the geoseroprevalence of the parasite may be due to local rainy conditions (because oocysts live longer in humid conditions), and low altitude regions (especially at mid-latitudes); a north-south seroprevalence gradient has also been reported in animals [9,95,96].

The seroprevalence of toxoplasmosis is high in immunocompromised patients, such as those infected with human immunodeficiency virus (HIV), and transplant or cancer patients treated with immunosuppressive agents [5,97,98].

It may be pointed out that the different serological methods used to obtain prevalence data are not standardized, and vary in sensitivity, specificity, and predictive values. As a consequence, no two tests produce the same results in all cases, even when carried out in the same laboratory [5].

Genotypes and virulence of T. gondii

T. gondii strains are highly diverse but only a few lineages are widely spread. Different genotypes of the parasite show great diversity in pathogenicity and drug sensitivity. Some atypical strains have also been detected. In Europe, North America, and Africa, there are three dominant clonal lineages of T. gondii called type I (RH, GT1,CAST), type II (ME49, WIL, HART), and type III (VEG, MOO, SOU), as well as many atypical genotypes which differ in prevalence, virulence, migratory capacity within the host, and ability to convert to the bradyzoite cyst phase [99–101]. Different strains of the parasite induce different cytokine responses [102], thus triggering development of various clinical and biochemical disturbances in the host, including modulation of the host cell proteome [103,104]. Mice fed as few as 1 oocyst of T. gondii serotype I and several atypical strains died of acute toxoplasmosis within 21 days post inoculation, while some T. gondii type II, and III strains were less virulent [105]. In North America, the parasite serotype II and NE-II causes congenital toxoplasmosis, while prematurity and severity of disease at birth was associated with the coccidjan NE-II serotype [106]. This serotype was also associated with rural residence, lower socioeconomic status and Hispanic ethnicity (P<0.01–0.001) [106]. A greater variety of genotypes are found in South America and Africa than in North America and Europe [107,108], suggesting that in these continents sexual replication of the parasite occurs more frequently than in any other part of the world [109]. This genetic divergence may contribute to the higher prevalence of seropositivity and ocular disease due to T. gondii, as exemplified by the higher prevalence of toxoplasmosis and Toxoplasma-induced eye disease in southern Brazil than in any other part of the world [110].

Transmission of T. gondii

Animals are infected by eating infected animals, by ingestion of or coming in contact with feces of an infected cat, or by transmission from mother to fetus. In humans, cats are the primary source of infection (contact with fecal material), but other pets may also be the secondary source of infection [3,111,112]. The seroprevalence of toxoplasmosis in the Arctic region proves that T. gondii can thrive in the absence of cats [113].

Contact with raw meat of infected animals, especially pork, is a more significant source of human infections in some countries, such as in Poland, where the majority of pigs, cattle and sheep (approximately 80%) test positive for T. gondii [8,114]. Transmission of the parasite can also occur by drinking municipal/well unboiled and unbottled water containing oocysts, exposure to contaminated soil, contaminated milk, exposure of children playing in sandpits, geophagia [115,116], eating raw or under-cooked meat, especially venison [117] or rabbits [118], raw oysters, clams, or mussels [119], consumption of unwashed raw fruits and vegetables contaminated with the oocyes [117], blood transfusion [120–122], maternal-fetal passage of blood cells (including placental trophoblasts) [123,124], solid organ allografts [125,126], bone marrow transplantation [127], allogeneic stem cell transplantation [128], sperm [129], breast milk [130,131], and semen [132] (thus, probably the infection may be transmitted via both vaginal and oral sex, significantly more frequently from seropositive to passive sex partner than vice-versa (P<0.001) [133]). Poor hygiene, lower socioeconomic status and less education, as well as exposure to certain strains of T. gondii may also contribute to a higher rate of infection [134].

Cellular mechanism(s) of infection

T. gondii is remarkable in its ability to invade a wide variety of host cells. Invasion is an active process relying on parasite motility and the sequential secretion of proteins from secretory organelles, the micronemes, rhoptries, and the dense granules. T. gondii can invade and multiply inside any nucleated cell type including epithelial cells and blood leukocytes [135]. A preference to infect as well as monocytes/macrophages function as systemic parasite transporters (“Trojan horses”) during infection [137–142]. The parasite can be transmitted from infected dendritic cells to NK cells [143], and several studies in mice indicate that the dendritic cells as well as monocytes/macrophages function as systemic parasite transporters (“Trojan horses”) during infection [137–142]. The parasite can be transmitted from infected dendritic cells to NK cells [143], and thus, low levels of NK cells found in pregnant women may suggest transmission of the parasite [144]. Differential infectivity and division rate of intracellular tachyzoites in human peripheral blood leukocytes and other primary human cells in vitro has been demonstrated depending on the cell characteristics [136].

Clinical manifestations of toxoplasmosis

It is believed that the majority of immunocompetent individuals infected with T. gondii remain asymptomatic or have a subclinical course with minor symptoms [145]. It is nevertheless the most common food-borne parasitic infection requiring hospital treatment [146], and the third most common cause of hospitalization due to food-borne infection [147]. Both competent and immuno-
| Country       | Prevalence (%) | Adj. Prevalence (%) | Reference | Period         | No.   |
|--------------|----------------|---------------------|-----------|----------------|-------|
| Albania      | 49             | 42                  | [10]      | 2004–2005      | 496   |
| Argentina    | 60             | 53                  | [11]      | 2001           | 1007  |
| Australia    | 23             | 16                  | [12]      | 2001           | 308   |
| Austria      | 42             | 36                  | [13]      | 1997           | 4601  |
| Bahrain      | 22             | 16                  | [14]      | 2005           | 3499  |
| Bangladesh   | 38             | 38                  | [15]      | 1995–1996      | 286   |
| Belgium      | 49             | 42                  | [16]      | 2004           | 16541 |
| Benin        | 54             | 47                  | [17]      | 1993           | 211   |
| Brazil       | 50             | 50                  | [18]      | 2012           | 2136  |
| Burkina Faso | 25             | 25                  | [19]      | 2006           | 336   |
| Cameroon     | 77             | 70                  | [20]      | 1992           | 1014  |
| Canada       | 20             | 17                  | [21]      | 2006           | NA    |
| Colombia     | 54             | 54                  | [22]      | 2006           | 630   |
| Costa Rica   | 76             | 76                  | [23]      | 1996           | 1234  |
| Croatia      | 29             | 24                  | [24]      | 2000           | 1109  |
| Cuba         | 55             | 55                  | [25]      | 2004           | 526   |
| Czech Republic | 20      | 16                  | [26]      | 2007           | 1053  |
| Congo        | 60             | 60                  | [27]      | 1990           | 2897  |
| Denmark      | 28             | 20                  | [28]      | 1999           | 89873 |
| Egypt        | 42             | 36                  | [29]      | 1995           | 62    |
| Estonia      | 68.6           | 45                  | [30]      | 1999–2000      | 1277  |
| Ethiopia     | 74             | 66                  | [31]      | 2012           | 1016  |
| Finland      | 20             | 17                  | [32]      | 1989           | 16733 |
| France       | 54             | 47                  | [33]      | 1995           | 13459 |
| Gabon        | 71             | 71                  | [34]      | 1997           | 767   |
| Germany      | 63             | 50                  | [35]      | 1999           | 4854  |
| Greece       | 25             | 21                  | [36]      | 2004           | 5532  |
| Grenada      | 57             | 50                  | [37]      | 2006           | 534   |
| Hungary      | 45             | 39                  | [38]      | 2000           | 31759 |
| Chile        | 39             | 33                  | [39]      | 1996           | 7536  |
| China        | 11             | 11                  | [40]      | 2006           | 235   |
| Iceland      | 13             | 8                   | [40]      | 1998           | 440   |
| India        | 35             | 35                  | [41]      | 2003           | 180   |
| Indonesia    | 53             | 46                  | [42]      | 2004           | 17735 |
| Iran         | 39             | 33                  | [43]      | 2007           | 576   |
| Iraq         | 49             | 42                  | [44]      | 2002           | 254   |
| Ireland      | 34             | 25                  | [45]      | 2008           | 20252 |
| Israel       | 21             | 17                  | [46]      | 1989           | 213   |
| Italy        | 23             | 16                  | [47]      | 2004           | 3426  |
| Jamaica      | 57             | 57                  | [48]      | 1986           | 1604  |
| Japan        | 10             | 8                   | [49]      | 2011           | 4466  |
| Jordan       | 47             | 40                  | [50]      | 2005           | 280   |
| Kuwait       | 46             | 53                  | [51]      | 2002–2005      | 225   |
| Lebanon      | 62             | 62                  | [52]      | 2010           | 232   |
| Libya        | 45             | 34                  | [53]      | 2007           | 143   |
| Lithuania    | 40             | 34                  | [54]      | 1991           | NA    |
| Macedonia    | 22             | 18                  | [55]      | 2005           | NA    |
| Madagascar   | 84             | 84                  | [56]      | 1992           | 599   |
| Malaysia     | 49             | 42                  | [57]      | 2003           | 200   |
| Mexico       | 49             | 49                  | [58]      | 2006           | NA    |
compromised persons can develop the disease, especially retino-choroiditis (ocular toxoplasmosis) [2,145,148]. In non-pregnant immunocompetent adults, acute disease may also lead to impaired eye sight [149,150]. For example, in the United States, one million new infections occur each year, which result in approximately 20,000 cases of retinal pathology [151]. Primary infection in pregnant women is a matter of great concern, since it can be transmitted to the fetus leading to spontaneous abortion or stillbirth. A newborn exposed to *T. gondii* in utero may develop congenital toxoplasmosis with major ocular and neurological consequences. In immunosuppressed (HIV, organ transplant or cancer) patients, the infection can lead to life-threatening cerebral toxoplasmosis [97,98,152].

Symptomatic infection with the parasite can be categorized into four groups: 1) cervical lymphadenopathy, headache, fever, sore throat, and myalgia, with possibility of splenomegaly and brief

| Country         | Prevalence (%) | Adj. Prevalence (%) | Reference | Period   | No.    |
|-----------------|----------------|---------------------|-----------|----------|--------|
| Montenegro      | 27             | 23                  | [55]      | NA       | NA     |
| Morocco         | 51             | 44                  | [59]      | 2007     | 2456   |
| Mozambique      | 19             | 13                  | [60]      | 2008     | 150    |
| Nepal           | 55             | 55                  | [61]      | 1998     | 345    |
| Netherlands     | 35             | 26                  | [62]      | 2004     | 7521   |
| New Zealand     | 35             | 26                  | [63]      | 2004     | 500    |
| Nigeria         | 78             | 71                  | [64]      | 1992     | 352    |
| Norway          | 11             | 9                   | [65]      | 1993     | 35940  |
| Pakistan        | 33             | 28                  | [66]      | 1997     | 105    |
| Papua New Guinea| 18             | 15                  | [67]      | 1990     | 197    |
| Peru            | 39             | 33                  | [68]      | NA       | NA     |
| Poland          | 40             | 34                  | [69]      | 2003     | 4916   |
| Portugal        | 24             | 17                  | [70]      | 2011     | 401    |
| Qatar           | 35             | 30                  | [71]      | 2005–2008| 1857   |
| South Korea     | 4              | 3                   | [72]      | 2000     | NA     |
| Romania         | 44             | 38                  | [73]      | 2008     | 184    |
| Sao Tome and Principe | 75 | 68              | [74]      | 2007     | 499    |
| Saudi Arabia    | 32             | 27                  | [75]      | 1991     | 921    |
| Senegal         | 40             | 34                  | [76]      | 1993     | 353    |
| Serbia          | 31             | 26                  | [55]      | 2007     | 765    |
| Singapore       | 17             | 14                  | [77]      | NA       | 120    |
| Slovakia        | 22             | 18                  | [78]      | 2008     | 656    |
| Slovenia        | 25             | 21                  | [79]      | 2002     | 21270  |
| Spain           | 32             | 23                  | [80]      | 2004     | 16362  |
| Sudan           | 42             | 36                  | [81]      | 2003     | 487    |
| Sweden          | 18             | 13                  | [82]      | 2001     | 40978  |
| Switzerland     | 35             | 26                  | [83]      | 2006     | NA     |
| Tanzania        | 35             | 35                  | [84]      | 1991     | 549    |
| Thailand        | 13             | 11                  | [83]      | 2001     | 1200   |
| Togo            | 75             | 68                  | [85]      | 1991     | 620    |
| Trinidad and Tobago | 43    | 43              | [86]      | 2008     | 450    |
| Tunisia         | 43             | 37                  | [87]      | 1996     | 2231   |
| Turkey          | 54             | 47                  | [88]      | 2005     | 1149   |
| United Arab Emirates | 23 | 19              | [89]      | 1997     | 1503   |
| UK              | 9              | 6                   | [90]      | 2005     | 1897   |
| USA             | 11             | 9                   | [91]      | 2007     | NA     |
| Venezuela       | 38             | 38                  | [92]      | 2006     | 446    |
| Vietnam         | 11             | 9                   | [93]      | 2003     | 300    |

The second and third column show prevalence of toxoplasmosis and prevalence adjusted to a standard age of 22 years to account for variation in childbearing age in across countries (column 1) using the formula Prevalence adj = 1−(1−Prevalence)^(22/childbearing age) [9]. Column 5 shows year(s) when the study was performed and column 6 shows number of women in the sample. For Macedonia, the 2004 WHO data were not available therefore this 30th European country was not included in our data set.

doi:10.1371/journal.pone.0090203.t001
erythematous (maculopapular) rash; 2) typhus-like exanematous form with myocarditis, meningoencephalitis, atypical pneumonia and possibly death; 3) retinochoroiditis, which may be severe, requiring enucleation; and 4) central nervous system involvement [153]. In addition, several reports suggest that T. gondii infection may be responsible for additional wide range of symptoms, and development of several clinical entities (summarized in Table 2).

Some of the clinical manifestations of T. gondii infection may be as a result of extensive interaction of the pathogen with approximately 3000 host genes or proteins possibly because of frequent host/pathogen antigen homology that disrupts/creates/ triggers host specific metabolic pathways, and finally contributes to the development of endophenotypes of different diseases [154]. The parasite and concomitant viral and/or bacterial infections scavenge important metabolites from host cells and/or donate other compounds to the host causing unwanted effects. In addition, T. gondii-derived autoantibodies also play an important role in the pathology associated with the parasite [154].

Association of seroprevalence of toxoplasmosis with other pathologies

Due to the fact that T. gondii infection is omnipresent and associated with development of many pathologies in humans and animals, including the disease burden of congenital toxoplasmosis, as represented by disability-adjusted life years (DALY) being the highest among all foodborne pathogens [149], the purpose of this work was to collectively evaluate available geoprimidemological data on the parasite worldwide national seroprevalence variations and their relationship with mortality and disability rates. In the analyses, gross domestic product (GDP) per capita as a covariate was used because earlier it was argued and demonstrated that culture-level correlations need to be controlled for regional socioeconomic parameters [9,215,322]. If possible (i.e. in multivariate GLM analyses), two potential confounding variables that could strongly influence both the survival of Toxoplasma oocysts in soil and a course of various diseases, namely the average latitude (proxy for temperature) and the average relative humidity of particular regions or different years we calculated an unweighted arithmetic mean. The obtained data were adjusted to a standard age and possibly death; 3) retinochoroiditis, which may be severe, requiring enucleation; and 4) central nervous system involvement [153]. In addition, several reports suggest that T. gondii infection may be responsible for additional wide range of symptoms, and development of several clinical entities (summarized in Table 2).

Some of the clinical manifestations of T. gondii infection may be as a result of extensive interaction of the pathogen with approximately 3000 host genes or proteins possibly because of frequent host/pathogen antigen homology that disrupts/creates/ triggers host specific metabolic pathways, and finally contributes to the development of endophenotypes of different diseases [154]. The parasite and concomitant viral and/or bacterial infections scavenge important metabolites from host cells and/or donate other compounds to the host causing unwanted effects. In addition, T. gondii-derived autoantibodies also play an important role in the pathology associated with the parasite [154].

Association of seroprevalence of toxoplasmosis with other pathologies

Due to the fact that T. gondii infection is omnipresent and associated with development of many pathologies in humans and animals, including the disease burden of congenital toxoplasmosis, as represented by disability-adjusted life years (DALY) being the highest among all foodborne pathogens [149], the purpose of this work was to collectively evaluate available geoprimidemological data on the parasite worldwide national seroprevalence variations and their relationship with mortality and disability rates. In the analyses, gross domestic product (GDP) per capita as a covariate was used because earlier it was argued and demonstrated that culture-level correlations need to be controlled for regional socioeconomic parameters [9,215,322]. If possible (i.e. in multivariate GLM analyses), two potential confounding variables that could strongly influence both the survival of Toxoplasma oocysts in soil and a course of various diseases, namely the average latitude (proxy for temperature) and the average relative humidity of particular countries have also been included into the statistical models. In this study we found many positive and some negative associations between the prevalence of toxoplasmosis and various diseases burdens. The number and strength of these associations were much higher than could be expected by chance. Still, it must be emphasized that statistical association does not mean causality. Based on the finding of a statistical association between two phenomena, one cannot determine which of them is the cause and which is the effect – in other words, whether event A causes event B, or whether event B causes event A. Not only we are unable to determine whether event A causes B, or B causes A, but sometimes there is an (unknown) event C that causes both A and B. Therefore, all effects observed in the present exploratory study as well as all suggested biological or medical interpretations must be considered just as potential stimuli for the next, more focused research (search for unknown confounders and for independent evidence) that must follow.

Methods

Mortality and Burden of Diseases data

The data on disease burden, mortality and Disability Adjusted Life Year (DALY), were obtained from the table “Mortality and Burden of Diseases Estimates for WHO Member States in 2004” published by WHO [323] and available at: www.who.int/ evidence/bod. The publication can be downloaded from the website: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html; accessed July 2013. Summary tables present the best estimates of WHO – based on the evidence available in mid-2006 – rather than from the official estimates of Member States. Methods and data sources are summarized in the Annexes of the “Global burden of disease: 2004 update” [323], and the methodology used is described in more details elsewhere [324]; also available at: http://www.dcp2.org/pubs/GBDX; accessed July 2013.

The Disability Adjusted Life Year (DALY) has been defined [323] as “a health gap measure that extends the concept of potential years of life lost due to premature death and also to include equivalent years of ‘healthy’ life lost by virtue of being in a state of poor health or disability.” Thus, the DALY combines in one measure the time lived with disability and the time lost due to premature mortality. One DALY can be thought of as one lost year of ‘healthy’ life, while the ‘burden of disease’ as a measure of the gap between current health status and an ideal situation where everyone lives into old age free of disease and disability. The method of calculation of age-standardized DALY has been described earlier [323].

Data collection for prevalence of toxoplasmosis

In the literature, most of toxoplasmosis prevalence (seroprevalence) data are available only for women in childbearing age. Therefore, all available data collected for this population were published mostly between 1995–2006; the final database was obtained from 80 countries (29 European). When more than one estimation of prevalence of toxoplasmosis was available for a particular country, we gave priority to multicenter studies performed between 1998–2004. When the studies published different prevalence data for various regions or different years we calculated an unweighted arithmetic mean. The obtained data were adjusted to a standard age 22 years to eliminate differences in prevalence caused by different childbearing ages in various countries [325] were kindly provided by Mudhakar Dama) using the formula:

\[
\text{Prevalence}_{adj} = 1 - (1 - \text{Prevalence})^{(22/\text{child bearing age})} \[9].
\]

Statistical Methods

All statistical tests except partial Kendall correlation test were performed independently with SPSS 21 and Statistica 10.0. The association between seroprevalence of toxoplasmosis and specific disease burden estimated with age standardized DALY was calculated using nonparametric partial Kendall correlation test [326,327] with Gross Domestic Product per capita (GDP) as covariate. Because the results of similar analyses performed with the General Linear Model (GLM) method were qualitatively the same, GLM data were primarily interpreted in the Discussion section of present study. The GLM is more sensitive for the quality of data (e.g. to presence of outliers and non-Gaussian distribution of data, etc.), however, it enables to control for more than one covariate. In the present analysis, we controlled for GDP, geographical latitude and annual mean of relative humidity of particular countries using data available at http://data.worldbank.org/indicator/NY.GDP.PCAP.CD (accessed 10.12. 2013) and http://www.climateperts.com/ (accessed 24. 2013). No formal corrections for multiple tests were carried out, however, the fraction of significant results largely exceeded a theoretical value of 5 false positive results per 100 tests.

The medical importance of the association was expressed as regression coefficient B, the slope of the regression line. The
Table 2. Diseases and clinical entities associated with *T. gondii* infection.

| Disease/Clinical entity                                                                 | References                                      |
|----------------------------------------------------------------------------------------|-------------------------------------------------|
| Congenital toxoplasmosis (encephalitis; chorioretinitis; neonatal mortality)            | [100,149,155–158]                               |
| Psychosis; schizophrenia; bipolar disorder                                              | [159–166]                                      |
| Mood disorders; suicide; depression (?)                                                 | [167–174]                                      |
| Obsessive-compulsive disorder                                                          | [175,176]                                      |
| Attention/concentration deficit hyperactivity disorder                                  | [175,177]                                      |
| Anorexia                                                                                | [178–181]                                      |
| Autism spectrum disorders                                                               | [164,177,182–185]                              |
| Down’s syndrome                                                                        | [182,186–188]                                  |
| Alzheimer’s disease                                                                     | [182,189–191]                                  |
| Parkinson’s disease                                                                     | [192,193]                                      |
| Migraine; other headaches                                                               | [194–197]                                      |
| Idiopathic intracranial hypertension                                                    | [177,180,198]                                  |
| Pseudotumor cerebri                                                                    | [180,198]                                      |
| Aseptic meningitis                                                                      | [180,198]                                      |
| Mollaret meningitis                                                                     | [199]                                           |
| Epilepsy                                                                                | [200,201]                                      |
| Aphasia and epilepsy (Landau-Kleffner syndrome)                                        | [202]                                           |
| Facial nerve palsy (Bell’s palsy)                                                       | [203]                                           |
| Hearing loss                                                                            | [204,205]                                      |
| Central diabetes insipidus; syndrome of inappropriate antidiuretic hormone secretion  | [156,206–209]                                  |
| Hypothalamo-pituitary dysfunction; panhypopituitarism                                   | [209–211]                                      |
| Brain tumors (meningioma; ependymoma; glioma)                                          | [196,212–216]                                  |
| Non-Hodgkin’s lymphoma                                                                  | [217,218]                                      |
| Neoplasia                                                                              | [216,219–221]                                  |
| Melanoma                                                                               | [216,222–226]                                  |
| Breast cancer                                                                          | [227]                                           |
| Carcinoma of female genitalia, including cervical tissue                               | [228]                                           |
| Chronic heart failure; myocarditis; arrhythmia                                         | [229–231]                                      |
| Inflammatory bowel disease                                                             | [232–234]                                      |
| Ulcerative colitis                                                                     | [232]                                           |
| Crohn’s disease                                                                        | [232]                                           |
| Celiac disease                                                                         | [232,235]                                      |
| Abdominal hernia                                                                        | [233,236]                                      |
| Hepatitis, including HCV infection                                                     | [237–246]                                      |
| Granulomatous liver disease                                                            | [247,248]                                      |
| Liver cirrhosis; granulomatous liver disease; impaired liver function                  | [242–244,249–253]                              |
| Primary biliary cirrhosis; biliary atresia; cholestatic disorders                      | [254–261]                                      |
| Diabetes mellitus type 1 and 2                                                          | [189,262–264]                                  |
| Goitre; iodine deficiency                                                               | [265–268]                                      |
| Hashimoto’s thyroiditis                                                                 | [269]                                           |
| Graves’ disease; thyroid adenoma                                                       | [269–271]                                      |
| Rheumatoid arthritis; Still’s disease                                                  | [272–277]                                      |
| Polymyositis                                                                           | [231,278–283]                                  |
| Systemic sclerosis                                                                      | [277,284,285]                                  |
| Systemic lupus erythematosus                                                           | [286]                                           |
| Wegener’s granulomatosis; other vasculitides                                           | 205; 215 [277,287]                             |
| Anti-phospholipid syndrome                                                              | [287]                                           |
| Cryoglobulinemia                                                                        | [287]                                           |
The present study showed that prevalence of toxoplasmosis correlated with specific disease burden measured with age-standardized DALY or with specific mortality in particular countries (Fig. 2).

Because distribution of DALY and mortality for many diseases was not normal, the analysis of association of toxoplasmosis prevalence with disease burden was performed with two methods, nonparametric partial Kendall correlation test and GLM analysis.

Since, a nonparametric partial Kendall correlation test enables to control for one confounding variable, we controlled for the GDP per capita because this variable is known to be strongly correlated with the quality of health care and therefore with the burden associated with many diseases. The partial Kendall correlation test demonstrated that age standardized DALY of 57 of 128 diseases and disease categories on the WHO list showed significant correlation (53 positive and 4 negative) with prevalence of toxoplasmosis in all (n = 88) countries after the effect of GDP was controlled, and further 8 diseases showed such trends (p<0.1) (6 positive and 2), see Fig. 3. Similar analyses for 29 European countries showed 12 significant correlations (11 positive and 1 negative) and 11 trends (10 positive and 1 negative), and for 59 non-European countries test revealed 33 significant correlations (29 positive and 4 negative) and 11 trends (10 positive and 1 negative), and for 59 non-European countries test revealed 33 significant correlations (29 positive and 4 negative) and 11 trends (10 positive and 4 negative), Fig 3.

GLM analyses with GDP, latitude and humidity as covariates showed that age standardized DALY of 23 of 128 diseases and disease categories on the WHO list had significant correlation (18 positive and 5 negative) with prevalence of toxoplasmosis in all (n = 88) countries after the effect of GDP was controlled, and further 12 diseases showed such trends (p<0.1) (all positive), see Fig. 4. Similar analyses for 29 European countries showed 32 significant correlations (29 positive and 3 negative) and 18 trends (16 positive and 2 negative), and for 59 non-European countries had 18 significant correlations (13 positive and 5 negative) and 13 trends (9 positive and 4 negative), Fig 4.
Correlation of toxoplasmosis prevalence with disease mortality

Partial Kendal correlation tests also showed that mortalities from 31 of 111 diseases and disease (WHO) categories with nonzero mortality had significant correlation (29 positive and 2 negative) with prevalence of toxoplasmosis in 88 countries after the effect of GNP was controlled, and further 6 diseases showed such trends (p<0.1) (5 positive and 2 negative), see Fig. 3. Similar analyses performed for 29 European countries demonstrated 6 significant correlations (all positive), and 11 trends (all positive) (here only 90 diseases had the mortality data necessary for analysis), and for 59 non-European countries showed 16 significant correlations (14 positive and 2 negative) and 8 trends (7 positive and 1 negative) (109 diseases had enough data for the analysis) (Fig. 3).

GLM analyses also showed that mortalities of 12 out of 111 diseases and disease categories (for 17 diseases the mortality data were available for less than 3 countries) revealed significant correlation (11 positive and 1 negative) with prevalence of toxoplasmosis in 88 countries after the effects of GDP, latitude humidity were controlled, and further 11 diseases showed such trends (10 positive and 1 negative), see Fig. 4. Similar analyses performed for 29 European countries showed 11 significant correlations (all positive) and 13 trends (all positive), and for 59 non-European countries had 11 significant correlations (8 positive and 3 negative) and 8 trends (7 positive and 1 negative), Fig. 4.

Several explanations may be put forward for positive correlation between prevalence of latent toxoplasmosis and the DALY or the morbidity from a particular disease: a) T. gondii infection may increase the risk of development of some diseases, b) certain diseases may increase the risk of acquiring toxoplasmosis, or c) some unknown factor(s) may increase both the risk of triggering certain diseases and Toxoplasma infection. Similarly, there are several possible explanations for the observed negative correlations: a) infection with the parasite can increase resistance/tolerance of the infected host to a certain disease by modulating its innate and/or acquired cellular/humoral immunity. For example, suppression of cellular immunity observed in in vivo as well as in vitro systems can make the host more sensitive to infection by certain pathogens, and at the same time protect it against development of some autoimmune diseases. On the other hand, chronic inflammation loci in tissues/organs can be responsible for inducing health problems, including development of certain tumors [214,215], and at the same time activation of the host immune system can make local tissue environment unfavorable for growing, proliferation and persistence of certain infectious agents. For example, toxoplasmosis increases dopamine levels in the brain tissue, which can protect the host against symptoms of certain diseases, e.g. Parkinson’s disease, and at the same time it can increase the risk for development of other pathologies, such as schizophrenia [330,331].

In the present GLM analyses, three potential confounding factors, the GDP per capita (which strongly correlates with quality of health services and hygienic standards), the geolatitude (which strongly correlates with temperature and quantity and quality of sunlight) and humidity which influences survival of Toxoplasma oocysts in soil), were controlled. However, many other factors, such as cultural habits, can also influence the risk of Toxoplasma infection, and/or other infections as well. It has been, for example, suggested that toxoplasmosis could be a sexually transmitted
disease (STD) transferred from men to women with semen/ejaculate [331,332]. This could explain the observed positive correlation between the prevalence of latent toxoplasmosis and DALY for several STDs. Finally, it is to be noted that the incidence of a certain disease can be decreased by an increased risk of death due to another concomitant disease.

In the next part of discussion, comments are made on the results obtained for particular diseases, mainly the results of GLM tests as the partial Kendall correlation tests can control for one confounding variable only and the regression coefficient (B-value) has more straightforward interpretation than Kendall Tau. We have concentrated on the age-standardized DALY data because only a subset of disease could result in the death of patients under normal conditions. The strength of correlation is usually estimated by $\eta^2$, which reflects fraction of variability of dependent variable that can be explained by an independent variable (here, by the prevalence of toxoplasmosis). The clinical relevance of a particular association is however better reflected by the regression coefficient $B$, which shows an increase of a dependent variable (here, the age standardized DALY expressed in years of life lost per 100,000 inhabitants) that corresponds to the increase of an independent variable per one unit (here, the increase of prevalence of toxoplasmosis by 1%). Therefore, the $B$-value reflects not only the strength of the correlation but also the incidence of particular disease.

**Association of seroprevalence of toxoplasmosis with specific diseases in all 88 countries**

**All disease burden.** Prevalence of toxoplasmosis explained about 23% of between-countries variability in mortality and age-standardized DALY in Europe (mortality: $B = 3.338$, $\eta^2 = 0.229$, $p = 0.024$; DALY: $B = 68.18$, $\eta^2 = 0.227$, $p = 0.014$). This association was not significant for non-European countries (mortality: $B = 3.37$, $\eta^2 = 0.026$, $p = 0.239$; DALY: $B = 92.49$, $\eta^2 = 0.030$, $p = 0.204$) or for all 88 countries (mortality: $B = 3.78$, $\eta^2 = 0.031$, $p = 0.104$; DALY: $B = 98.287$, $\eta^2 = 0.034$, $p = 0.093$). Both communicable and noncommunicable diseases were responsible for the observed association in Europe, however, for communicative infection was significant only for DALY (mortality: $B = 0.024$, $\eta^2 = 0.007$, $p = 0.878$; DALY: $B = 11.44$, $\eta^2 = 0.166$, $p = 0.039$).

**Noncommunicable diseases.** The highest regression coefficient ($B = 26.33$, $p = 0.019$) was found for the entire category of noncommunicable diseases. In this case, a difference of 1% in the prevalence of toxoplasmosis corresponded to a difference of 26.33 years of healthy life lost per 100,000 inhabitants.
| All Causes | Mortality in Africa | Mortality in Europe | Excess All | Excess Africa | Excess All Africa |
|-----------|-------------------|--------------------|-----------|-------------|------------------|
| 1. Communicable, maternal, perinatal and nutritional conditions | 88 | 0.0177 | 0.0166 | 0.0000 | 0.0000 | 0.0000 |
| 2. Cardiovascular diseases | 86 | 0.0869 | 0.0039 | 0.0000 | 0.0000 | 0.0000 |
| 3. Respiratory diseases | 85 | 0.0091 | 0.0041 | 0.0000 | 0.0000 | 0.0000 |
| 4. Digestive diseases | 84 | 0.0105 | 0.0036 | 0.0000 | 0.0000 | 0.0000 |
| 5. Neoplasms | 83 | 0.0037 | 0.0035 | 0.0000 | 0.0000 | 0.0000 |
| 6. Endocrine, nutritional, and metabolic diseases | 82 | 0.0020 | 0.0020 | 0.0000 | 0.0000 | 0.0000 |
| 7. Mental and behavioral disorders | 81 | 0.0013 | 0.0013 | 0.0000 | 0.0000 | 0.0000 |
| 8. Multi-system organ failure due to poisoning | 80 | 0.0011 | 0.0011 | 0.0000 | 0.0000 | 0.0000 |
| 9. Intentional self-harm | 79 | 0.0007 | 0.0007 | 0.0000 | 0.0000 | 0.0000 |
| 10. Other causes | 78 | 0.0005 | 0.0005 | 0.0000 | 0.0000 | 0.0000 |

**Correlation of Toxoplasmosis with Disease Burden**
DALY per 100,000 inhabitants. The prevalence of toxoplasmosis explained 6.4% of between countries variability in DALY.

Cardiovascular diseases. The second highest regression coefficient (B = 12.49, p = 0.026, Eta^2 = 0.058) was observed for cardiovascular diseases. However, prevalence of toxoplasmosis explained about 15% of variability in mortality attributed to cardiovascular diseases in European countries subset (B = 18.23, p = 0.048, Eta^2 = 0.155). Also, in the European countries, the difference in prevalence of toxoplasmosis explained about 17% of variability of ischemic heart disease (B = 8.59, p = 0.039, Eta^2 = 0.166). Stronger correlations between prevalence of toxoplasmosis and heart disease, especially inflammatory heart disease, were revealed with nonparametric partial Kendall test (comparing the data in tables shown in Fig. 3 and 4). One may suggest that the non-Gaussian distributions of dependent variables, e.g. a bimodal distribution for cerebrovascular and cardiovascular disease and highly skewed distribution for hypertensive, rheumatic and inflammatory heart diseases (results not shown), were responsible for the false negative results of the GLM tests.

Theoretically, the inability to control for more than one confounding variable (here, the latitude and annual precipitation) in the distribution-robust nonparametric tests could be responsible for the false positive results of the partial Kendall test. However, the present data do not support this explanation. Fig. 1 shows that the latitude correlates negatively and the humidity positively with the prevalence of toxoplasmosis. The Kendall correlation test showed, for example, the positive association between hypertensive heart disease and prevalence of toxoplasmosis (DALY: B = 0.749, p = 0.008), while GLM demonstrated lack of such association (DALY: B = 0.345; mortality: p = 0.282). The negative association between prevalence of toxoplasmosis and latitude (see above) could explain the positive correlation between the disease burden for hypertensive heart disease and prevalence of toxoplasmosis, because the disease burden for hypertensive heart disease correlated negatively with the latitude (DALY: B = −3.846, Eta^2 = 0.139, p<0.001), but also negatively with humidity (B = −2.145, Eta^2 = 0.059, p = 0.024), which is in contradiction to the explanation. However, the negative correlation between prevalence of toxoplasmosis and latitude could not explain the positive correlation between prevalence of toxoplasmosis and the inflammatory heart disease (DALY: B = 0.012, mortality: p = 0.006), because inflammatory heart disease correlated positively with latitude (B = 0.749, Eta^2 = 0.010, p = 0.362), and negatively with humidity (B = −1.392, Eta^2 = 0.041, p = 0.060). This contradicts the notion that the correlations with the latitude or humidity could be responsible for the association between toxoplasmosis and cardiovascular diseases detected with the partial Kendall correlation tests.

Perinatal conditions. The third highest regression coefficient (B = 9.66) was demonstrated for this category, but, it explained only 3.3% of the variability making the correlation non-significant (p = 0.097). The important components of this category were prematurity and low birth weight (B = 3.43; Eta^2 = 0.053; p = 0.034). Published data suggest that early development of embryos in mothers with latent toxoplasmosis was slower, although, the birth weight of newborns was approximately the same as those of infection-free mothers [26]. These studies were performed in Czech Republic, a developed European country, with low frequency of virulent T. gondii strains. It is possible that the effect of toxoplasmosis on development of embryos is qualitatively different in other parts of the world. It is indicative that the association between prevalence of toxoplasmosis and DALY for prematurity and low birth weight is much weaker for the European countries (B = 0.320; Eta^2 = 0.004; p = 0.761) than for others. Once again, the correlation of DALY for perinatal conditions with prevalence of toxoplasmosis detected with nonparametric tests were stronger than those detected with GLM. Here, however, the correlation observed in Kendall test (in which the GDP but not the latitude and humidity was controlled) can be explained by correlation of both prevalence of toxoplasmosis and the DALY for perinatal conditions, controlling for the latitude, because the latter correlation is negative and relatively strong (and significant).

Congenital abnormalities. The regression coefficient was only medium (B = 2.61; Eta^2 = 0.133; p<0.001). The correlation was significant for the 88 countries, however, it was non-significant for the European countries (B = 1.90; Eta^2 = 0.137; p = 0.062). Interestingly, more than 55 years ago, it was observed that children with Down syndrome had a much higher probability of having mothers with latent toxoplasmosis (84%) than normal children (32%) [333]; the probability of having fathers with latent toxoplasmosis did not differ between children with and without this disorder. Recently, it has been suggested that Down syndrome may be caused by congenital T. gondii infection [182], Table 2. This hypothesis is supported by the finding that T. gondii has a specific protein transporter exposed at the parasite surface, with high affinity for folic acid, which is responsible for the acquisition and salvaging of exogenous folate compounds [187], thus leading to folate deficiency in the host. The transport of folic acid across the parasite plasma membrane was found to be rapid, biphasic, bidirectional, specific, and concentration- and temperature-dependent, and methotrexate, an antifolate, was found to be internalized by the protozoan pathogen to the mitochondrion [187]. In addition, it has been demonstrated that simultaneous dietary restriction of folic acid and infection with T. gondii induces DNA damage in peripheral blood cells of infected mice [186]. Furthermore, T. gondii infection was also associated with nutritional deficiencies of iron and iodine [266,334,335], which may lead to have adverse effect on the growth and development of the fetus.

Principally different explanation of the observed association suggest results of three studies on the influence of toxoplasmosis on secondary sex ratio and on the rate of prenatal and early postnatal development of children of infected mothers. These results indicate that latent toxoplasmosis could protect the embryos with less serious developmental disturbances against spontaneous abortion [26,336–338]. It is possible that such beneficial activity of the parasite could translate into positive correlation between prevalence of toxoplasmosis and incidence and severity of congenital abnormalities.

Lymphatic filariasis. The regression coefficient was medium (B = 4.53; Eta^2 = 0.140, p = 0.072). This disease occurs in 27 countries of our data set and therefore the highly non-Gaussian distribution of DALY (and mortalities) makes the results of GLM analysis not fully credible. The nonparametric test showed no significant association between filariasis and toxoplasmosis. How-
## Correlation of Toxoplasmosis with Disease Burden

| All Causes | Cancer | Cardiovascular Disease | Diabetes | Chronic Renal Disease | Neurological Disease | Nephritis | Pneumonia and Other Respiratory Disease | Pending | Inflammatory Disease | Other Causes | Injuries | Total |
|------------|--------|------------------------|----------|-----------------------|--------------------|---------|--------------------------------------|---------|---------------------|-------------|----------|-------|---------|
| All Causes | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Cancer     | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Cardiovascular Disease | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Diabetes   | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Chronic Renal Disease | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Neurological Disease | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Nephritis   | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Pneumonia and Other Respiratory Disease | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Pending    | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Inflammatory Disease | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |
| Other Causes | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 1.0000 | 0.9894 | 1.0000 | 0.9894 | 1.0000 |

### Notes

- The table above represents the correlation coefficients between different disease categories and Toxoplasmosis.
- Each cell [i,j] contains the correlation coefficient between the disease category i and j.
- Values close to 1 indicate a strong positive correlation, while values close to 0 indicate no correlation.

### References

1. [Source 1](#)
2. [Source 2](#)
3. [Source 3](#)
ever, possible relationship between toxoplasmosis and filariasis could theoretically be explained by the fact that *T. gondii* usually disseminates via lymphatic system in the infected patients, who usually have symptomatic lymphadenopathy. In addition, possible interactions exist between toxoplasmosis-associated changes in the host lymphatic system and a progressive clinical picture of lymphatic filariasis (Table 2). Filariasis may therefore represent another co-morbidity of the host infected with *T. gondii*.

**Measles.** The regression coefficient was medium (B = 4.124; Eta² = 0.070; p = 0.137), and the correlation was not significant. A possible association, if it really exists, is difficult to rationalize, however, latent cerebral toxoplasmosis could influence susceptibility to measles because of changes in the immune status of the children (Table 2) [339,340] caused by the parasite or measles-mumps-rubella (MMR) vaccination.

**Asthma.** The regression coefficient B was 1.290 (Eta² = 0.071; p = 0.014). An opposite direction association was observed for European (B = −1.571, Eta² = 0.096, p = 0.124) and non-European (B = 1.879, Eta² = 0.158, p = 0.002) countries. We have no explanation for the positive association, but, the negative association between *T. gondii* infection and asthma could be, at least partially, explained by the anti-inflammatory effect of histamine produced in excess in asthmatic patients, since, asthma is a chronic inflammatory disorder associated with an increased number of T helper type 2 (T helper type 2) cells producing anti-inflammatory cytokines and decreased number of T helper type 1 cells generating pro-inflammatory cytokines. Histamine modulates the cytokine T helper 1/T helper 2 balance because it enhances secretion of T helper 2 cytokines, such as IL-4, IL-5, IL-10, and IL-13, and inhibits production of T helper 1 interleukins (IL-2, IFN-γ, and monokine IL-12) [341], thus exerting beneficial anti-inflammatory effects.

**Epilepsy.** Epilepsy had a small regression coefficient (B = 0.972; Eta² = 0.112, p = 0.001), but the correlation was highly significant. This association was observed both in European (B = 0.816, Eta² = 0.193, p = 0.025) and non-European countries (B = 0.967, Eta² = 0.125, p = 0.007). The association between latent toxoplasmosis and cryptic epilepsy has already been suggested to exist on the basis of the case control studies – for example, see Ref. [342,343] Table 2.

**Leukemia.** Surprisingly, there was a strong association between toxoplasmosis and DALY for leukemia in European countries (B = 0.445, Eta² = 0.216, p = 0.017) explaining about 22% of variability in DALY. In a small study performed in 15 patients with leukemia, 10 (66.7%) individuals had increased serum IgG, and 2 also had increased IgM antibodies to *T. gondii* [219]. It is known that tachyzoites of *T. gondii* concentrate of testosterone as observed in *Toxoplasma*-infected male rats [350] and men [351,352]. Histopathologic studies of the reproductive system in male sheep experimentally infected with the parasite showed inflammatory process in the prostate gland and seminal vesicles strongly suggestive of *Toxoplasma* infection [300] (Table 2). Thus, persistent chronic inflammation caused by the parasite also must be taken into account in the development of prostate cancer, although perhaps having different clinical courses in European versus non-European countries.

**Obsessive compulsive disorder.** Obsessive compulsive disorder (OCD) had a B value of 0.836, but the prevalence of toxoplasmosis explained 28.7% of total variability in DALY (p < 0.001). For European countries the association was weaker (B = 0.681, Eta² = 0.212, p = 0.018), but for non-European countries, it was nearly twice higher (B = 0.925, Eta² = 0.338, p < 0.001). The association between latent toxoplasmosis and OCD has already been suggested to exist on the basis of results of a case-control study [176], in which the authors found 47.6% seroprevalence of toxoplasmosis among OCD patients (n = 42) and only 19% prevalence in controls (n = 100). Both neurotransmitters, dopamine and serotonin, are expected to play an important role in OCD. It is possible that either an increased concentration of dopamine, synthesized by two enzymes encoded in *T. gondii* genome, and a decreased level of serotonin, the metabolite of tryptophan degradation – the part of the host defense against parasitic infection – could be important etiologic factors in the development of OCD. Incidentally, OCD is not an uncommon disease (incidence of about 3%) and is probably associated with an increased risk of suicide [353–356]. It can be speculated that an association between toxoplasmosis and OCD could, in part, be responsible for the increased risk of suicides reported in *Toxoplasma*-infected individuals. It is possible that the nearly twice stronger relationship between toxoplasmosis and OCD in European (Eta² = 0.292) than in non-European (Eta² = 0.360) countries could somehow be related with the negative, not positive, relationship between the prevalence of toxoplasmosis and incidence of suicides in non-European countries observed in our study, see below.
**Endocrine disorders.** A regression coefficient (B) of 2.118 was observed for the category of ‘endocrine disorders’. The prevalence of toxoplasmosis explained about 5.8% of total variability (p = 0.020) and non-significant trends were observed for both European and non-European countries. The positive and negative associations between toxoplasmosis and testosterone concentration were observed for men and women, respectively. However, our unpublished data suggest that toxoplasmosis could also play a role in the production of thyroid hormones. This finding is supported by recent literature data demonstrating the prevalence of anti-Toxoplasma IgG antibodies in patients with thyroid autoimmunity [277,337] as well as in many other autoimmune diseases, as compared with controls (Table 2). The autoantibody burden has also been demonstrated even in non-autoimmune individuals during infections [338]. Patients with autoimmune diseases frequently present neurologic manifestations [359], and this may further support the significant prevalence of toxoplasmosis in patients with endocrine disorders, because central nervous system is the most immunoprivileged organ for *T. gondii* dissemination and settlement in the host. Fetal [360] and maternal microchimerism, acting as a “Trojan horse” in dissemination of the parasite, could play an important role in endocrine and other health disorders [361].

**Sexually transmitted diseases (STDs).** A regression coefficient (B) of 1.63 was observed for the general category of ‘sexually transmitted diseases except AIDS’. Prevalence of toxoplasmosis explained 4.1% of variability (p = 0.063). The association was stronger in European countries (B = 0.413, Eta² = 0.215, p = 0.017) than in non-European countries (B = 1.699, Eta² = 0.041, p = 0.133). Similar effects were observed for gonorrhea (B = 0.175, Eta² = 0.213, p = 0.018) and chlamydia (B = 0.229, Eta² = 0.209, p = 0.019) in Europe, but were different for non-European countries for gonorrhoea (B = 0.549, Eta² = 0.069, p = 0.049) and chlamydia (B = 0.287, Eta² = 0.050, p = 0.097). We believe that the correlation of both prevalence of toxoplasmosis and STD with other factor(s), such as a risky sexual behavior (promiscuity and frequent unprotected sex) is responsible for the observed positive association between prevalence of toxoplasmosis and age/controlled DALY for STDs. It has been suggested by other investigators [332] that *Toxoplasma* is frequently transmitted by ejaculate in several animal species. An indirect evidence exists that the same could also occur in humans [331]. Practicing oral sex or even kissing may also be another important route of wide dissemination of the parasite among sexual partners, in addition to intercourse.

**Pertussis.** Pertussis had a regression coefficient (B) of 1.81. Prevalence of toxoplasmosis explained 10% of variability in DALY (p = 0.003). This correlation could, at least in part, be rationalized by the findings that in some instances immunization could shorten the incubation period of certain diseases or convert a latent infection/inflammation into clinically active disease. The necessary precondition for such an occurrence is the presence of latent infection or asymptomatic bacterial/viral-parasitic colonization [362]. It has been reported that some infants and young children develop various urinary tract diseases, such as acute renal failure, nephrotic syndrome, or pyelonephritis, after the injection of the whole-cell DTP vaccine [363]. Administration of DTP vaccine caused dose-, and time-dependent biological changes in animals, including increased hepatic mRNA expression for several cytokines, marked inhibition of liver CYP450 enzymes activity, induction of IFN-γ, and enhanced NOS mRNA expression [364,365]. In addition, a significant increase in toxoplasma-cysts was observed in brain tissues of mice exposed to both *T. gondii* infection and methylmercury (thimerosal, a vaccine preservative) versus the parasite alone [366]. Thus, it seems that a concomitant use of strong lipopolysaccharide antigen (a component of the whole-cell pertussis) and thimerosal exerted serious synergistic adverse health effects when given to individuals with latent central nervous system *T. gondii* infection [104,340]. It is not clear, however, whether the incidence of pertussis correlates with intensity of DPT vaccination.

**Childhood cluster diseases.** The regression coefficient was high (B = 4.24), and it explained 4.9% of variability (p = 0.041). The high regression coefficient is not surprising because, for example, respiratory tract diseases are the most frequent cause of hospitalization and death in children and *T. gondii* infection is extensively prevalent worldwide [148,367]. There are many predisposing, provocative, facilitating, and other factors, such as chronic hypoxia, viral infections/bacterial toxins, inflammatory states, biochemical disorders, and genetic abnormalities that are the most likely triggers of development of respiratory tract diseases, including sudden infant death syndrome [368]. For example, exposure of children to cigarette smoke (second-hand) increased their susceptibility to viral and bacterial infections because children who died of sudden infant death syndrome had markedly higher concentration of cotinine (a metabolite of nicotine) in their lung tissue and pericardial fluid than in controls [369,370]. Thus, negative effects of latent toxoplasmosis on children’s physiology, including function of the immune system, may markedly affect clinical course of diseases in children and might significantly affect disease severity and mortality.

**Suicides.** Latent toxoplasmosis was found to be associated with an increased risk of attempted suicides [161,170,171,371]. The results of earlier correlation studies performed for 17–20 European countries [172,173] were confirmed by the present study, wherein a positive trend was observed for the 29 European countries (B = 4.05, p = 0.065, Eta² = 0.135), but, this correlation could not be detected for the entire 88 countries. In fact, a negative correlation between risk of suicide and prevalence of latent toxoplasmosis was found for the 59 non-European countries (B = -2.157, p = 0.012, Eta² = 0.11). We have no explanation for this qualitative difference between European and non-European countries. However, the existence of positive correlation between the prevalence of latent toxoplasmosis and violence [174] was confirmed by partial Kendall correlation for all countries (Tau = 0.244, p = 0.001) and non-European countries (Tau = 0.276, p = 0.002), but not for European countries (Tau = 0.065, p = 0.619), the GLM method showed just a trend for European countries (see tables shown in Fig. 3 and Fig. 4).

**Traffic accidents.** On the basis of four published case-control studies, a positive correlation was expected between the burden of traffic accidents and prevalence of latent toxoplasmosis. However, this correlation was significant in nonparametric tests (mortality: Tau = 0.148, p = 0.042; DALY: Tau = 0.164, p = 0.023). Weak correlation in other tests may be caused by the fact that the traffic accident rates depend on many confounding variables, including the number of vehicles in circulation, length of the road network, mean number of kilometers (miles) travelled by one inhabitant per year, driver behavior (alcohol/drug use, sleep deprivation, etc.), etc. Probably, much stronger correlations would be detected when these variables would be included into the models. Interestingly, the strongest association of latent toxoplasmosis and traffic accidents was found for RhD negative drivers [372], while the RhD positive subjects, especially RhD positive heterozygotes seem to be relatively protected against impairment of reaction times [373,374] as well as against traffic accidents [372]
Correlation of Toxoplasmosis with Disease Burden

Limitations of the study
It is possible that some of the toxoplasmosis prevalence data are inaccurate, as there are no published national survey data of latent toxoplasmosis carried out systematically. In addition, surveys performed in a relatively small, and ethnically and sociologically homogeneous population, such as in the Czech Republic, demonstrate that seroprevalence of toxoplasmosis varies considerably in different regions of the country. Therefore, it is difficult to estimate the average prevalence of this clinical entity in women of child-bearing age in a particular country on the basis of one or two studies performed in one hospital or even in one city. Furthermore, it is important to point out that the different serological methods used to obtain toxoplasmosis seroprevalence data are not standardized, and vary in sensitivity, specificity, and predictive values. As a consequence, no two tests produce the same results in all cases, even when carried out in the same laboratory [5].

For the present study, probably most of available data for the period 1995–2008 were collected, and published information for period prior to 1995 was also considered. To maximally avoid possible subjective bias, we completed our data set on January 2013 and did not change it after starting the analyses despite of the fact that data for other four countries appeared during 2013. To further decrease the risk of subjectivity in selection of countries, we included available data for all countries; our data set contained the prevalence of toxoplasmosis in 88 countries, which represented the largest ever data set analyzed in all toxoplasmosis correlation studies. To increase the reliability of our results, we confirmed the results of parametric GLM analysis with the nonparametric Kendall test, which is less sensitive to contamination of data with few incorrect values. It may be noted that lack of precision in the prevalence data increases the risk of false negative results of the obtained correlation studies.

Conclusions
The present results suggest that the prevalence of latent toxoplasmosis in particular countries correlated (mostly positively) with various disease burden measured with age standardized Disability Adjusted Life Years or with age standardized mortality. It must be emphasized that no epidemiological study and especially no correlation (ecological) study can prove existence of causal relation between the two factors. At the same time, results of such studies could indicate which hypothesis should be tested in the future. It is highly probable that some of the observed correlations represent “false correlations” – either the Type 1 errors of used statistical tests or the expression of existence of unknown factor(s) that correlates with both the risk of latent toxoplasmosis and incidence (or severity) of particular disease. However, it is also highly probable that at least some of the observed correlations do occur because toxoplasmosis is, up to now rarely suspected, etiological agent of particular diseases. Existence of some correlations could be expected to happen on the basis of our present knowledge for certain diseases (for example, epilepsy, obsessive compulsive disorder, congenital abnormalities). Some of the obtained correlations may be regarded as rather surprising and should therefore be studied in more detail in the future. In the opinion of the authors, slowly emerging important role of latent toxoplasmosis in etiology of several clinical entities deserves much more attention and financial support in future clinical research.

Author Contributions
Conceived and designed the experiments: JF. Analyzed the data: JF. Contributed reagents/materials/analysis tools: JF. Wrote the paper: JF JP ZI. Data collection: MS.

References
1. Nicolle C, Manceaux I. (1908) Sur une infection à corps de Leishman (ou organismes voisins) du gondi. C R Acad Sci (Paris) 147: 763–766.
2. Furtado JM, Smith JR, Bellott R, Jr, Gately D, Winthrop KL. (2011) Toxoplasmosis: a global threat. J Glob Infect Dis 3: 281–294.
3. Dubey JP, Beatie CP. (1988) Toxoplasmosis of animals and man. Boca Raton, Fla.: CRC Press. pp. 1–220.
4. Dubey JP. (1998) Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 28: 1019–1024.
5. Tenter AM, Heeckroth AR, Weiss LM. (2000) Toxoplasma gondii: from animals to humans. Int J Parasitol 30: 1217–1258.
6. Jones JL, Kruuson-Moran D, Wilson M, McQuillan G, Navin T, et al. (2001) Toxoplasma gondii infection in the United States: Seroprevalence and risk factors. Am J Epidemiol 154: 357–365.
7. Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, et al. (2011) Foodborne illness acquired in the United States-major pathogens. Emerg Infect Dis 17: 7–15.
8. Pavlovska Z. (1994) Toxoplasmosis. In: Januszkievicz J, editor. The outline of infectious diseases in the clinic. 2nd ed. Warsaw: PZWL. pp. 214–218.
9. Laferney KD. (2006) Can the common brain parasite, Toxoplasma gondii, influence human culture? Proc R Soc Biol Sci Ser B 273: 2749–2755.
31. Dubey JP, Tiao N, Gebreyes WA, Jones JL (2012) A review of toxoplasmosis in pregnant women in Albania. New Microbiol 32: 89–92.

10. Maggi P, Volpe A, Carito V, Schinaia N, Bino S, et al. (2009) Surveillance of toxoplasmosis in pregnant women in Albenga, Italy. Microbiol Res 164: 717–721.

26. Kanárková S, Flegr J (2007) Longer pregnancy and slower fetal development in women with latent toxoplasmosis. Int J Hyg Environ Health 210: 139–145.

30. Birgisdottir A, Asbjornsdottir H, Cook E, Gislason D, Jansson C, et al. (2006) Susceptibility of pregnant women to Toxoplasma gondii infection. Acta Trop 99: 251–253.

25. Sanchez-Gutierrez A, Martin-Hernandez I, Garcia-Izquierdo SM (2003) Seroprevalence of Toxoplasma in the female population of the County of Split Dalmatia, Croatia. Eur J Epidemiol 18: 375–377.

15. Ashrafunnessa, Shahla K, Islam MN, Huq T (1998) Seroprevalence of Toxoplasma gondii antibodies. A case control study. J Egypt Soc Parasitol 28: 877–882.

14. Tabbara KS, Saleh F (2005) Serodiagnosis of toxoplasmosis in Bahrain. Saudi Med J 26: 1383–1386.

20. Ndumbe PM, Andela A, Nkemnkengasong J, Watonsi E, Nyambi P (1992) Prevalence of toxoplasmosis during pregnancy—an epidemiologic survey over 22 consecutive years. J Perinat Med 20: 211–214.

37. Asthana SP, Macpherson CN, Weiss SH, Stephens R, Denny TN, et al. (2006) Seroprevalence of Toxoplasma gondii infection amongst pregnant women in Assam, India. Indian J Med Microbiol 24: 431–432.

39. Contreras MC, Schenone H, Salinas P, Sandwalk L, Rojas A, et al. (2009) Seropidemiology of human toxoplasmosis in Chile. Rev Inst Med Trop Sao Paulo 51: 431–435.

16. Breugelmans M, Naessens A, Foulon W (2004) Prevention of toxoplasmosis in pregnant women. Gent Eur J Public Health 6: 261–264.

19. Yabbara KS, Saleh F (2005) Serodiagnosis of toxoplasmosis in Saudi Arabia. J Infect Dev Ctries 09: 1363–1365.

38. Szenasi Z, Horvath K, Sarkany E, Melles M (2005) Toxoplasmosis surveillance in Mediterranean Europe. World Acad Sci 19: 95–102.

54. Rockiene L (1997) The prognosis of congenital toxoplasmosis in Lithuania. Zentralbl Gynaecol 121: 83–85.

59. El Mansouri B, Rhajaoui M, Sebti F, Amarir F, Laboudi M, et al. (2007) Prevalence of toxoplasmosis in pregnant women from Morocco. Rev Inst Med Trop Sao Paulo 50: 713–716.

63. Morris A, Croxson M (2004) Serological evidence of Toxoplasma gondii infection in a hospital antenatal clinic: a seroepidemiological survey. P N G Med J 48: 28–31.

68. Cantella R, Colichon A, Lopez L, Wu C, Goldfarb A, et al. (1974) Prevalence of Toxoplasma gondii antibodies in pregnant women. Rev Soc Bras Med Trop 41: 163–171.

58. Caballero-Ortega H, Uribe-Salas FJ, Conde-Glez CJ, Cedillo-Pelaez C, Watterson A, et al. (2009) Toxoplasmosis in pregnant women in Antananarivo (Madagascar). Bull Soc Pathol Exot Filial 88: 46–49.

62. Konishi E, Houki Y, Harano K, Mibawani RS, Marsudi D, et al. (2000) High prevalence of antibodies to Toxoplasma gondii in Indonesian pregnant women. Trop Geo 18: 730–733.

42. Konishi E, Houki Y, Harano K, Mibawani RS, Marsudi D, et al. (2000) High prevalence of antibodies to Toxoplasma gondii in Indonesian pregnant women. Trop Geo 18: 730–733.

50. Sakikawa M, Noda S, Hanaoka M, Nakayama H, Hojo S, et al. (2012) Anti-TOXOPLASMA antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin Vaccin Immunol 19: 365–367.

21. Sanz-Díez R, Giraldez A, Merino A, Valero R, Soto G, et al. (2009) Decreased rate of congenital toxoplasmosis in Spain. J Pediatr Infect Dis Soc 8: 143–145.

35. Sanchez-Gutierrez A, Martin-Hernandez I, Garcia-Izquierdo SM (2003) Estudio de reactividad a Toxoplasma gondii en embarazadas de las provincias Ciudad de la Habana y Pinar del Rio, Cuba. Lab Enferm Infec 28: 3–8.

34. Saheb J, Gara M, Karunajeewa H, Siebert D, Hammond R, et al. (2001) Toxoplasmosis in a dermatology hospital antenatal clinic: a seroepidemiological survey. J Coll Phys Surg Pak 11: 156–159.

64. Jenum PA, Kapperud G, Stray-Pedersen B, Melby KK, Eskild A, et al. (1998) Prevalence of Toxoplasma gondii antibodies in maternal serum and cord blood in a prospective study. Scand J Infect Dis Suppl 84: 70–74.

22. Kayakova S, Fleury S. Longer pregnancy and slower fetal development in women with latent “asymptomatic” toxoplasmosis BMC Infect Dis 7: art: 114.

11. Karunajeewa H, Siebert D, Hammond R, Garland S, Kelly H (2001) Toxoplasmosis and HIV infection in the female population of the County of Split Dalmatia, Croatia. Eur J Epidemiol 16: 875–877.

5. Sanchez-Gutierrez A, Martin-Hernandez I, Garcia-Izquierdo SM (2003) Estudio de reactividad a Toxoplasma gondii en embarazadas de las provincias Ciudad de la Habana y Pinar del Rio, Cuba. Lab Enferm Infec 28: 3–8.

23. Kayakova S, Fleury S. Longer pregnancy and slower fetal development in women with latent “asymptomatic” toxoplasmosis BMC Infect Dis 7: art: 114.

12. Karunajeewa H, Siebert D, Hammond R, Garland S, Kelly H (2001) Toxoplasmosis and HIV infection in the female population of the County of Split Dalmatia, Croatia. Eur J Epidemiol 16: 875–877.

65. Jenum PA, Kapperud G, Stray-Pedersen B, Melby KK, Eskild A, et al. (1998) Prevalence of Toxoplasma gondii antibodies in maternal serum and cord blood in a prospective study. Scand J Infect Dis Suppl 84: 70–74.

36. Jenum PA, Kapperud G, Stray-Pedersen B, Melby KK, Eskild A, et al. (1998) Prevalence of Toxoplasma gondii antibodies in maternal serum and cord blood in a prospective study. Scand J Infect Dis Suppl 84: 70–74.

33. Kanárková S, Flegr J (2007) Longer pregnancy and slower fetal development in women with latent toxoplasmosis. Int J Hyg Environ Health 210: 139–145.

32. Konishi E, Houki Y, Harano K, Mibawani RS, Marsudi D, et al. (2000) High prevalence of antibodies to Toxoplasma gondii in Indonesian pregnant women. Trop Geo 18: 730–733.

31. Dubey JP, Tiao N, Gebreyes WA, Jones JL (2012) A review of toxoplasmosis in humans and animals in Ethiopia. Epidemiol Infect 140: 1935–1938.

28. Kosoikini M, Lappalainen M, Koskela P, Hedman K, Ammla P, et al. (1992) The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study. Scand J Infect Dis Suppl 84: 70–74.

29. Kosoikini M, Lappalainen M, Koskela P, Hedman K, Ammla P, et al. (1992) The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study. Scand J Infect Dis Suppl 84: 70–74.

30. Birgisdottir A, Asbjornsdottir H, Cook E, Gislason D, Jansson C, et al. (2006) Seroprevalence of Toxoplasma gondii in the female population of the County of Split Dalmatia, Croatia. Eur J Epidemiol 16: 875–877.

24. Kosoikini M, Lappalainen M, Koskela P, Hedman K, Ammla P, et al. (1992) The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study. Scand J Infect Dis Suppl 84: 70–74.

25. Sanchez-Gutierrez A, Martin-Hernandez I, Garcia-Izquierdo SM (2003) Estudio de reactividad a Toxoplasma gondii en embarazadas de las provincias Ciudad de la Habana y Pinar del Rio, Cuba. Lab Enferm Infec 28: 3–8.

26. Kanárková S, Flegr J (2007) Longer pregnancy and slower fetal development in women with latent toxoplasmosis. Int J Hyg Environ Health 210: 139–145.

31. Dubey JP, Tiao N, Gebreyes WA, Jones JL (2012) A review of toxoplasmosis in humans and animals in Ethiopia. Epidemiol Infect 140: 1935–1938.
Correlation of Toxoplasmosis with Disease Burden

A. Jokelainen, A. Nareaho, A. Oksanen, A. Jokelainen P

Background: Toxoplasmosis is a zoonosis caused by Toxoplasma gondii, which can cause a range of clinical disease in immunocompetent and immunocompromised patients, predominantly in pregnant women and newborns. The aim of this study was to systematically review the correlation of Toxoplasmosis with disease burden.

Methods: A systematic review was conducted using Medline, Embase, and Scopus databases. The search terms included “Toxoplasmosis” and “disease burden.” The inclusion criteria were studies published in English, with human subjects, and those that assessed the correlation of Toxoplasmosis with disease burden.

Results: A total of 20 studies were included in the review. The studies showed a range of disease burdens associated with Toxoplasmosis, including congenital toxoplasmosis, maternal infection during pregnancy, and infections in immunocompromised patients. The correlation of Toxoplasmosis with disease burden was assessed through various methods, including seroprevalence, incidence, and infection rate studies.

Conclusion: The correlation of Toxoplasmosis with disease burden is significant, and further research is needed to better understand the impact of Toxoplasmosis on human health and disease burden.
Correlation of Toxoplasmosis with Disease Burden

218. Ribeiro DA, Pereira PCM, Machado JM, Silva SB, Pessoa AWP, et al. (2004) Does toxoplasmosis cause DNA damage? An evaluation in isogenic mice under normal diet or dietary restriction. Mutat Res - Gen Tox En 559: 169–176.

219. Massimine KM, Doan LT, Atreya CA, Stedman TT, Anderson KS, et al. (2005) Toxoplasma gondii is capable of causing effective folate transport - A likely expansion of the JTL family of transmembrane proteins. Mol Biochem Parasitol 144: 44–54.

220. Al-Gazali LI, Padmanabhan R, Melnyk S, Yi P, Pogribny IP, et al. (2001) Abnormal folate metabolism and genetic polymorphism of the folate pathway in a child with Down syndrome and neural tube defect. Am J Med Genet 103: 128–132.

221. Rao AA, Sridhar GR, Das UN (2007) Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses 69: 1272–1276.

222. Kusbeci OY, Miman O, Yaman M, Aktepe OC, Yazar S (2011) Could Toxoplasma gondii have any role in Alzheimer disease? Alzheimer Dis Assoc Disord 25: 1–3.

223. Chan MF, Gurnot C, Monine TJ, Souven AJ, Guthrie KA, et al. (2012) Male microchimerism in the human female brain. PLoS ONE 7: e45592.

224. Minam O, Kusbeci OY, Aktepe OC, Getinkaya Z (2010) The probable relation between Toxoplasma gondii and Parkinson's disease. Neurosci Lett 475: 129–131.

225. Murakami T, Nakajima M, Nakamura T, Hara A, Uyama E, et al. (2000) Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection. Intern Med 39: 1111–1114.

226. Kosoglu E, Yazar S, Koc I (2009) Is Toxoplasma gondii a causal agent in migraine? Am J Med Sci 338: 120–122.

227. Prandota J (2010) Migrant associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood desaturation. Int J Neurosci 120: 81–87.

228. Prandota J (2009) The importance of Toxoplasma gondii infection in diseases presenting with headaches. Headaches and aseptic meningitis may be manifestations of the Jarisch-Herxheimer reaction. Int J Neurosci 119: 2144–2152.

229. Prandota J (2007) Recurrent headache as the main symptom of acquired cerebral toxoplasmosis in nonhuman immunodeficiency virus-infected subjects with no lymphadenopathy: the parasite may be responsible for the neuropenic inflammation postulated as a cause of different types of headaches. Am J Ther 14: 105–109.

230. Kusbeci OY, Minam O, Yaman M, Aktepe OC, Yazar S (2011) Could Toxoplasma gondii have any role in Alzheimer disease? Alzheimer Dis Assoc Disord 25: 1–3.

231. Prandota J (2009) Mollaret meningitis may be caused by reactivation of latent cerebral toxoplasmosis. Int J Neurosci 119: 1655–1692.

232. Palmer BS (2007) Meta-analysis of three case controlled studies and an ecological study into the link between cryptogenic epilepsy and chronic toxoplasmosis infection. Seizure 16: 657–663.

233. Strommelm EM, Seguin R, Thadadha VM, Schwartzman JD, Gilbert K, et al. (2001) Cryptogenic epilepsy: an infectious etiology? Epilepsia 42: 436–438.

234. Michalowicz R, Jozwiak S, Ignatowicz R, Szwabowska-Orzeszko E (1988) Update on the diagnosis and management of toxoplasmosis in a population of patients with no lymphadenopathy: the parasite may be responsible for the neurogenic oxygen desaturation. Int J Neurosci 120: 81–87.

235. Ryan P, Hurley SF, Johnson AM, Salberg M, Lee MW, et al. (1993) Tumours and Toxoplasmosis complicated by central diabetes insipidus in an infant with Down syndrome. Brain Dev 18: 75–77.

236. Oygur N, Yilmaz G, Ozkaynak C, Guven AG (1998) Central diabetes insipidus due to toxoplasmosis complicated by neonatal hypernatremia. J Pediatr Endocrinol Metab 11: 141–144.

237. Bars L, Hecht Y, Callard P, Ferrier JP (1978) Hepatitis due to acquired Toxoplasma gondii infection. Acta Paediatr Scand 67: 332–347.

238. Lappin MR (2010) Update on the diagnosis and management of toxoplasmosis in Saudi children: a hospital based study. Int J Pediatr Otorhinolaryngol 74: 21–28.

239. Siahanidou T, Tsoumas D, Kanaka-Gantenbein C, Mandyla H (2006) Neuroendocrine abnormalities in a neonate with congenital toxoplasmosis detected by newborn screening. J Pediatr Endocrinol Metab 19: 1363–1366.

240. Roca B, Calabuig C, Arenas M (1992) Toxoplasmosis and hepatitis. Med Clin (Barc) 89: 595–596.

241. Vethayangam A, Bryceson AD (1976) Acquired toxoplasmosis presenting as hepatitis. Trans R Soc Trop Med Hyg 70: 524–525.

242. Lampon N, Hermida-Cadahia EF, Rivero A, Tutor JC (2012) Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol 11: 356–363.

243. Das UN (2007) Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med Sci Moni 13: RA214–221.
MacSween RN, Galbraith I, Thomas MA, Watkinson G, Ludlam GB (1973)

Al-Masri AN, Flemming P, Rodeck B, Melter M, Leonhardt J, et al. (2006)

de Oliveira Fdos S, Kieling CO, dos Santos JL, de Leon Lima PP, Vieira S, et al. (2013)

Glassman MS, Dellalzedah S, Beneck D, Seashore JH (1991)

Fitzgerald JF (1988)

Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, et al. (2014)

Prandota J (2013)

Toxoplasma gondii

259. Al-Masri AN, Flemming P, Rodeck B, Melter M, Leonhardt J, et al. (2006)

de Oliveira Fdos S, Kieling CO, dos Santos JL, de Leon Lima PP, Vieira S, et al. (2013)

Glassman MS, Dellalzedah S, Beneck D, Seashore JH (1991)

Fitzgerald JF (1988)

Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, et al. (2012)

254. Shapira Y, Agmon-Levin N, Renaudineau Y, Porat-Katz BS, Barzilai O, et al. (2012)

253. Da Silva AS, Tonin AA, Thorstenberg ML, Leal DB, Fighera R, et al. (2013)

252. Bermudez LE, Covaro G, Remington J (1993)

251. Ustun S, Aksoy U, Dagi C, Eroz G (2004)

250. Coach M, Forouhar F, Wu CH, Wu GY (2012)

249. Akgun MV, Yilmaz A, Aydin T (2009)

248. Bertoli F, Espino M, Arosemena JR, Fishback JL, Frenkel JK (1995)

247. Bertoli F, Espino M, Arosemena JR, Fishback JL, Frenkel JK (1995)

246. Fitzgerald JF (1988) Cholestatic disorders of infancy. Pediatr Clin North Am

245. Glassman MS, Dellalzedah S, Beneck D, Seashore JH (1991) Coincidence of

244. Vasquez-Garibay EM, Romero-Velasco E (2009) Iodine deficiency in relation to

243. Golce C, Yazar S, Bayram F, Gundogun K, Yaman O, et al. (2008) Anti-

242. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, et al. (2009)

241. Slosarkova S, Literak I, Skrivanek M, Svobodova V, Suchy P, et al. (1999)

240. Suhardjo, Utomo PT, Agni AN (2003) Clinical manifestations of ocular toxoplasmosis in children treated at a reference center for congenital toxoplasmosis in the

239. Marani L, Venturi S (1986) [Iodine and delayed immunity]. Minerva Med 77:

238. Tozzoli R, Barzilai O, Ram M, Villalta D, Bizzaro N, et al. (2008) Infections

237. Singh S, Singh N, Pandav R, Pandav CS, Karmarkar MG (1994)

236. Marani L, Venturi S (1986) [Iodine and delayed immunity]. Minerva Med 77:

235. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, et al. (2009) Anti-infectious

234. Karasawa T, Takizawa I, Morita K, Ishibashi H, Kanae K, et al. (1991)

233. Cuomo G, D’Albresca V, Rizzo V, Nardelli S, La Montagna G, et al. (2013)

232. Karasawa T, Takizawa I, Morita K, Ishibashi H, Kanae K, et al. (1991)

231. Chan WF, Atkins CJ, Naysmith D, van der Westhuizen N, Woo J, et al. (2012)

230. Krause I, Anaya JM, Fraser A, Barzilai O, Ram M, et al. (2009) Infectious

229. Suharjo, Utomo PT, Agni AN (2003) Clinical manifestations of ocular toxoplasmosis and iodine deficiency in Angora goats. Vet Parasitol 81: 89–97.

228. Abdoli A, Dalimi A, Movahedin M (2012) Impaired reproductive function of
toxoplasmosis due to ovarian dysfunction. Parasitol Res 81: 109–113.

227. Suharjo, Utomo PT, Agni AN (2003) Clinical manifestations of ocular toxoplasmosis and iodine deficiency in Angora goats. Vet Parasitol 81: 89–97.

226. Stahl W, Kaneda Y, Tanabe M, Kumar SA (1995) Uterine atrophy in chronic
toxoplasmosis due to ovarian dysfunction. Parasitol Res 81: 109–113.

225. Stahl W, Dias JA, Turek G, Kanesel Y (1995) Etiology of ovarian dysfunction in chronic murine toxoplasmosis. Parasitol Res 81: 114–129.

224. Toftad GC, Cao Y, Joiner KA (1992) Laminin on Toxoplasma gondii meditates parasite binding to the beta 1 integrin receptor alpha beta 6 beta 1 on human foreskin fibroblasts and Chinese hamster ovary cells. Infect Immun 60: 4925–4931.

223. Abdullah A, Dulißen A, Mølhavek M (2012) Impaired reproductive function of
toxoplasmosis and iodine deficiency in Angora goats. Vet Parasitol 81: 89–97.

222. Abou-El-Enein MM, El-Shafie MS, Abdel-Baky MS, Aly MM (1988) Toxoplasma seropositivity in patients with rheumatoid arthritis. J Egypt Soc Parasitol 18: 385–391.

221. Torrey EF, Yolken RH (2003) The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav Immun 13: 401–410.

220. Balleri E, Cunto M, Accardo S (1991) Adult-onset Still's disease associated to
Toxoplasma gondii infection. Clin Rheumatol 10: 326–327.

219. Chan WJ, D’Menche M, Nyamuthi D, van der Westhuizen N, Woo J, et al. (2012) Microchimerism in the rheumatoid nodules of patients with rheumatoid arthritis. Arthritis Rheum 64: 380–388.

218. Shapira Y, Agmon-Levin N, Selmi C, Petrıkova J, Barzilai O, et al. (2012)

217. Suharjo, Utomo PT, Agni AN (2003) Clinical manifestations of ocular toxoplasmosis and iodine deficiency in Angora goats. Vet Parasitol 81: 89–97.

216. Prandota J (2013)

215. Singh S, Singh N, Pandav R, Pandav CS, Karmarkar MG (1994)

214. Terpsidis KI, Papazahariadou MG, Taitzoglou IA, Papaioannou NG, Georgiadis MP, et al. (2009) Toxoplasma gondii infection & its association with iodine deficiency in a residential school in Greece. Int J Clin Exp Med 2: 345–351.

213. Terpsidis KI, Papazahariadou MG, Taitzoglou IA, Papaioannou NG, Georgiadis MP, et al. (2009) Toxoplasma gondii infection & its association with iodine deficiency in a residential school in Greece. Int J Clin Exp Med 2: 345–351.

212. Terpsidis KI, Papazahariadou MG, Taitzoglou IA, Papaioannou NG, Georgiadis MP, et al. (2009) Toxoplasma gondii infection & its association with iodine deficiency in a residential school in Greece. Int J Clin Exp Med 2: 345–351.

211. Terpsidis KI, Papazahariadou MG, Taitzoglou IA, Papaioannou NG, Georgiadis MP, et al. (2009) Toxoplasma gondii infection & its association with iodine deficiency in a residential school in Greece. Int J Clin Exp Med 2: 345–351.
305. Wickborn B, Winberg J (1972) Coincidence of congenital toxoplasmosis and acute nephritis in two infants. Speculations and pathogenesis. Am J Dis Child 133: 842–845.

306. Pavlovska-Kamenjak A, Moszczynska-Juchkiewicz A, Papierkowski A (1998) [Hensel-Schuelenpurpa and toxocarosis]. Pol Merkur Lekarski 4: 217–218.

307. Hamidou MA, Gueglio B, Cassagneau E, Trewick D, Grolleau JY (1999) Toxoplasmosis and ischemic injury in newborns. Pediatr Nephrol 13: 850-853.

308. Coppens I (2006) Contribution of host lipids to Toxoplasma pathogenesis. Cell Microbiol 8: 1–9.

309. Charron AJ, Sibley LD (2002) Host cells: mobilizable lipid resources for the intracellular parasite Toxoplasma gondii. J Cell Sci 115: 3049–3059.

310. Schleg A, Bettel S, Pypaert M, Wanke MR, Kaasch A, et al. (2005) Peculiariies of host cholesterol transport to the unique intracellular vacuole containing Toxoplasma. Traffic 6: 1125–1141.

311. Webster JP, Lambert PHL, Donnelly CA, Torrey EF (2006) Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-paracite medication on Toxoplasma gondii’s ability to alter host behaviour. Proc R Soc Biol Sci Ser B 273: 1023–1030.

312. Berdoy M, Webster JP, Macdonald DW (2000) Fatal attraction in rats infected with Toxoplasma gondii. Proc R Soc Biol Sci Ser B 267: 1591–1594.

313. Flegr J, Kodym P, Tolarova V (2000) Correlation of duration of latent Toxoplasma gondii infection with personality changes in women. Biol Psychol 53: 57–68.

314. Dana MS (2012) Parasite stress predicts offspring sex ratio. PLoS ONE 7.

315. WHO (2008) The Global Burden of Disease: 2004 update. Geneva: World Health Organization.

316. Lopez AD (2006) Global burden of disease and risk factors. New York, NY, Washington, DC: Oxford University Press, World Bank. 475 p.

317. Hollander E, Stein DJ, Kwon JH, Ahn MH, Ahmad HAH, Cha GH, et al. (2010) Toxoplasma gondii infection induces lipid metabolism alterations in the murine host. Mem Inst Oswaldo Cruz 104: 175–178.

318. Critchley EM, Vakil SD, Hutchinson DN, Taylor P (1982) Toxoplasma, Toxocara, and epilepsy. Epilepsia 23: 315–321.

319. Fok’s JM, Arriggi RB, Weidner JM, Kumar Menon S, Jin Z, et al. (2012) GalAergic signaling is linked to a hyperergic phenotype in dendritic cells infected by Toxoplasma gondii. PLoS Pathog 8: e1002736.

320. Kim YJ, Jho HA, Cho MW, Song YI, Hwang JH, et al. (2011) Toxoplasma gondii infection decreases social avoidance behavior in BALB/c mice. Arch Toxicol 85: 843–853.

321. Cannon AE, Vakil SD, Hutchinson DN, Taylor P (1982) Toxoplasma, Toxocara, and epilepsy. Epilepsia 23: 315–321.

322. Packard KA, Khan MM (2003) Effects of histamine on Th1/Th2 cytokine signals. Int J Med Microbiol 296: 105-106.

323. Vyas A (2013) Parasite-augmented mate choice and reduction in innate fear in females infected with Toxoplasma gondii. J Cell Sci 126: 1517–1526.

324. Flegr J, Lindova J, Pivonkova V, Havlicek J (2008) Brief Communication: latent toxoplasmosis. Clin Exp Immunol 149: 167–180.

325. Florenties E, Vakil SD, Hutchinson DN, Taylor P (1982) Toxoplasma, Toxocara, and epilepsy. Epilepsia 23: 315–321.

326. Vyas A (2013) Parasite-augmented mate choice and reduction in innate fear in females infected with Toxoplasma gondii. J Cell Sci 126: 1517–1526.

327. Hwang IY, Quan JH, Ahn MH, Ahmed HAH, Cha GH, et al. (2010) Toxoplasma gondii infection induces lipid metabolism alterations in the murine host. Mem Inst Oswaldo Cruz 104: 175–178.

328. Wasserman EE, Nelson K, Rose NR, Rhode C, Pillion JP, et al. (2009) Toxoplasma gondii infection confers resistance against BinSy-induced apoptosis by preventing the activation and mitochondrial targeting of pro-apoptotic Bax. J Cell Sci 122: 3511–3521.

329. Hesse D, Vutova P, Hacker G, Gross U, Luder CGK (2006) Toxoplasma gondii infection inhibits host cell apoptosis triggered by both intrinsic and extrinsic proapoptotic signals. Int J Med Microbiol 296: 109-116.

330. Lin A, Kumar V, Hari Dass SA, Vyas A (2013) Toxoplasma gondii infection enhances teratogenic steroidalogenesis in rats. Mol Endocrinol 22: 102–110.

331. Flegr J, Lendvai J, Pirovskova V, Havlik J (2009) Brief Communication: latent toxoplasmosis and salivary testosterone concentration-important confounding factors in second to fourth digit ratio studies. Am J Phys Anthropol 137: 479–484.

332. Flegr J, Lendvai J, Kodym P (2008) Sex-dependent toxoplasmosis-associated differences in testosterone concentration in humans. Parasitology 135: 427–431.

333. Prandota J (2012) Increased generation of antibodies and autoantibodies after Toxoplasma gondii infection. Acta Trop 119: 94–99.

334. Dijkman MA, Gueglio B, Cassagneau E, Trewick D, Grolleau JY (1999) Toxoplasmosis and ischemic injury in newborns. Pediatr Nephrol 13: 850-853.

335. Hwang IY, Quan JH, Ahn MH, Ahmed HAH, Cha GH, et al. (2010) Toxoplasma gondii infection induces lipid metabolism alterations in the murine host. Mem Inst Oswaldo Cruz 104: 175–178.

336. Kim YJ, Jho HA, Cho MW, Song YI, Hwang JH, et al. (2011) Toxoplasma gondii infection decreases social avoidance behavior in BALB/c mice. Arch Toxicol 85: 843–853.

337. Hesse D, Vutova P, Hacker G, Gross U, Luder CGK (2006) Toxoplasma gondii infection inhibits host cell apoptosis triggered by both intrinsic and extrinsic proapoptotic signals. Int J Med Microbiol 296: 109-116.

338. Lin A, Kumar V, Hari Dass SA, Vyas A (2013) Toxoplasma gondii infection enhances teratogenic steroidalogenesis in rats. Mol Endocrinol 22: 102–110.

339. Flegr J, Lendvai J, Pirovskova V, Havlik J (2009) Brief Communication: latent toxoplasmosis and salivary testosterone concentration-important confounding factors in second to fourth digit ratio studies. Am J Phys Anthropol 137: 479–484.

340. Flegr J, Lendvai J, Kodym P (2008) Sex-dependent toxoplasmosis-associated differences in testosterone concentration in humans. Parasitology 135: 427–431.
363. Prandota J (2004) Urinary tract diseases revealed after DTP vaccination in infants and young children. Cytokine irregularities and down-regulation of cytochrome P-450 enzymes induced by the vaccine may uncover latent diseases in genetically predisposed subjects. Am J Ther 11: 344–353.

364. Ansher SS, Thompson W (1994) Modulation of hepatic mRNA levels after administration of lipopolysaccharide and diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP vaccine) to mice. Hepatology 20: 904–911.

365. Fantuzzi G, Sironi M, Delgado R, Cannoni L, Rizzardini M, et al. (1994) Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicity. Infect Immun 62: 29–32.

366. King MD, Lindsay DS, Holladay S, Ehrich M (2003) Neurotoxicity and immunotoxicity assessment in CBA/J mice with chronic Toxoplasma gondii infection and single-dose exposure to methylmercury. Int J Toxicol 22: 53–61.

367. Pappas G, Roussos N, Falagas ME (2009) Toxoplasmosis snapshots: Global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 39: 1385–1394.

368. Prandota J (2004) Possible pathomechanisms of sudden infant death syndrome: key role of chronic hypoxia, infection/inflammation states, cytokine irregularities, and metabolic trauma in genetically predisposed infants. Am J Ther 11: 517–546.

369. McMartin KI, Platt MS, Hackman R, Klein J, Smalek JE, et al. (2002) Lung tissue concentrations of nicotine in sudden infant death syndrome (SIDS). J Pediatr 140: 265–269.

370. Milerad J, Vege A, Opdal SH, Rognum TO (1998) Objective measurements of nicotine exposure in victims of sudden infant death syndrome and in other unexpected child deaths. J Pediatr 133: 232–236.

371. Arling TA, Yolken RH, Lapidus M, Langenberg P, Dickerson FB, et al. (2009) Toxoplasma gondii antibody titers and history of suicide attempts in patients with recurrent mood disorders. J Nerv Ment Dis 197: 905–908.

372. Fleg J, Klose J, Novotná M, Berenreiterová M, Havlíček J (2009) Increased incidence of traffic accidents in Toxoplasma-infected military drivers and protective effect RhD molecule revealed by a large-scale prospective cohort study. BMC Infect Dis 9: art. 72.

373. Novotná M, Havlíček J, Smith AP, Kolbeková P, Skallová A, et al. (2008) Toxoplasma and reaction time: Role of toxoplasmosis in the origin, preservation and geographical distribution of Rh blood group polymorphism. Parasitology 135: 1253–1261.

374. Fleg J, Novotná M, Lindová J, Havlíček J (2006) Neurophysiological effect of the Rh factor. Protective role of the RhD molecule against Toxoplasma-induced impairment of reaction times in women. Neuroendocrinol Lett 29: 475–481.

375. Fleg J, Hampl R, Černochová D, Preus M, Bříková M, et al. (2012) The relation of cortisol and sex hormone levels to results of psychological, performance, IQ and memory tests in military men and women. Neuroendocrinol Lett 33: 224–235.

376. Overfield J, Hamer D, Dawson M (2007) Introduction to the Rh blood group system. Oxfordshire, U.K.: Scion Publishing.